Chiung-Wen Hu 1 , Yan-Zin Chang , Hsiao-Wen Wang , Mu-Rong Chao . Show Affiliations »
Abstract
BACKGROUND: Areca nut and tobacco are commonly used drugs worldwide and have been frequently used in combination. We describe the use of on-line solid-phase extraction and isotope-dilution liquid chromatography-tandem mass spectrometry for the simultaneous measurement of five major urinary metabolites of both areca nut and tobacco alkaloids, namely, arecoline, arecaidine, N-methylnipecotic acid, nicotine, and cotinine. METHODS: Automated purification of urine was accomplished with a column-switching device. After the addition of deuterium-labeled internal standards, urine samples were directly analyzed within 13 minutes. This method was applied to measure urinary metabolites in 90 healthy subjects to assess areca nut/tobacco exposure. Urinary time course of arecoline, arecaidine, and N-methylnipecotic acid was investigated in five healthy nonchewers after oral administration of areca nut water extracts. RESULTS: The limits of detection were 0.016 to 0.553 ng/mL. Interday and intraday imprecision were <10%. Mean recoveries of five metabolites in urine were 97% to 114%. Mean urinary concentrations of arecoline, arecaidine, N-methylnipecotic acid, nicotine, and cotinine in regular areca nut chewers also smokers were 23.9, 5,816, 1,298, 2,635, and 1,406 ng/mg creatinine, respectively. Time course study revealed that after administration of areca nuts extracts, the major urinary metabolite was arecaidine with a half-life of 4.3 hours, followed by N-methylnipecotic acid with a half-life of 7.9 hours, and very low levels of arecoline with a half-life of 0.97 hour. CONCLUSIONS: This on-line solid-phase extraction liquid chromatography-tandem mass spectrometry method firstly provides high-throughput direct analysis of five urinary metabolites of areca nut/tobacco alkaloids. IMPACT: This method may facilitate the research into the oncogenic effects of areca nut/tobacco exposure. ©2010 AACR.
BACKGROUND: Areca nut and tobacco are commonly used drugs worldwide and have been frequently used in combination. We describe the use of on-line solid-phase extraction and isotope-dilution liquid chromatography-tandem mass spectrometry for the simultaneous measurement of five major urinary metabolites of both areca nut and tobacco alkaloids, namely, arecoline , arecaidine , N-methylnipecotic acid , nicotine , and cotinine . METHODS: Automated purification of urine was accomplished with a column-switching device. After the addition of deuterium -labeled internal standards, urine samples were directly analyzed within 13 minutes. This method was applied to measure urinary metabolites in 90 healthy subjects to assess areca nut /tobacco exposure. Urinary time course of arecoline , arecaidine , and N-methylnipecotic acid was investigated in five healthy nonchewers after oral administration of areca nut water extracts. RESULTS: The limits of detection were 0.016 to 0.553 ng/mL. Interday and intraday imprecision were <10%. Mean recoveries of five metabolites in urine were 97% to 114%. Mean urinary concentrations of arecoline , arecaidine , N-methylnipecotic acid , nicotine , and cotinine in regular areca nut chewers also smokers were 23.9, 5,816, 1,298, 2,635, and 1,406 ng/mg creatinine , respectively. Time course study revealed that after administration of areca nuts extracts, the major urinary metabolite was arecaidine with a half-life of 4.3 hours, followed by N-methylnipecotic acid with a half-life of 7.9 hours, and very low levels of arecoline with a half-life of 0.97 hour. CONCLUSIONS: This on-line solid-phase extraction liquid chromatography-tandem mass spectrometry method firstly provides high-throughput direct analysis of five urinary metabolites of areca nut /tobacco alkaloids. IMPACT: This method may facilitate the research into the oncogenic effects of areca nut /tobacco exposure. ©2010 AACR.
Entities: Chemical
Disease
Species
Mesh: See more »
Substances: See more »
Year: 2010
PMID: 20713654 DOI: 10.1158/1055-9965.EPI-10-0483
Source DB: PubMed Journal: Cancer Epidemiol Biomarkers Prev ISSN: 1055-9965 Impact factor: 4.254